Introduction
Worldwide, breast cancer accounts for 15% of all cancer deaths in women. 1 Although early detection through mammography, improved diagnostic technology, and improved treatments have evolved, 2 the prevalence of breast cancer continues to rise in many parts of the world, including South America, Africa, and Asia, 3 and mortality from breast cancer remains a global issue. 7 Mutations in BLM, WRN, or RECQL4, located on chromosomes 15q26.1, 8p12 and 8q24.3 respectively, were found to be associated with some diseases in humans. 8 Less clear is whether dysregulation of RecQ-family expression is related to an increased risk of cancer. RECQL is overexpressed in multiple myeloma and associated with poor prognosis, 9 and the expression of RECQL is correlated with tumorigenesis in breast cancer. 10 Recent studies also showed that abnormal expression of the BLM protein might lead to the development of malignant tumors, [11] [12] [13] while overexpression of BLM stimulates DNA injury and induces sensitivity to cisplatin chemotherapy in triple-negative breast cancer. 14 WRN is considered a tumor suppressor, and it has been shown to inhibit tumor growth in nude mouse xenograft models of breast cancer. 15 RECQL4 is overexpressed in breast cancer cell lines, and depletion of RECQL4 facilitates apoptosis. 16 Arvind et al assessed RECQL5 expression in breast cancers, and found that expression levels of RECQL5 were associated with aggressive phenotypes and poor survival outcomes. 17 The prognostic roles of each RecQ member, especially at the mRNA level, remain poorly understood in breast cancer.
Therefore, the aims of this study were to use an online Kaplan-Meier plotter database to investigate the prognostic role of mRNA expression of the five RecQ DNA-helicase family members -RECQL, BLM, WRN, RECQL4, and RECQL5 -and clinical outcomes in women with breast cancer. We also confirmed the protein-expression levels of WRN and RECQL4 by immunohistochemistry (IHC) in breast cancer tissue.
Methods

Use of online databases, including Kaplan-Meier Plotter
The association of RecQ family member mRNA expression with prognostic value was analyzed using the online Kaplan-Meier Plotter breast cancer database (http://kmplot. com/analysis/index.php), which was produced using geneexpression data and survival information downloaded from the Gene Expression Omnibus (http://www.ncbi.hlm.nih. gov/geo). 18 
Breast cancer patient-outcome data
At the time of the study, the Kaplan-Meier Plotter database was capable of evaluating the effect of mRNA expression levels of 54,675 genes on patient survival using 10,641 cancer samples, which included breast cancer, 18 ovarian cancer, 19 lung cancer, 20 and gastric cancer. 21 There were 3,955 breast cancer patients with relapse-free survival (RFS) data, 1,402 with overall survival (OS) data, 1,747 with distant metastasisfree survival (DMFS) data, and 414 with postprogression survival (PPS) data. ER, PR, HER2, and lymph-node status, tumor grade, intrinsic breast-tumor subtype, and TP53 geneexpression data were collected and analyzed.
Tissue microarrays (TMAs) and IHC staining
TMAs were purchased from Outdo Biotech (Shanghai, China), and contained 160 breast cancer samples. Detailed clinicopathological characteristics of breast cancer samples are provided in Table S1 . Approval from the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine was obtained for the experiments. IHC staining of the TMAs was performed using primary antibodies against WRN (ab200; Abcam, Cambridge, UK) or RECQL4 (25470002; Novus Biologicals, Littleton, CO, US). Briefly, paraffin slides were baked at 60°C overnight, deparaffinized with 100% xylene, and rehydrated in graded ethanol. After antigen retrieval and inactivation of endogenous peroxidases, slides were preincubated in 10% normal goat serum and incubated with WRN (1:200) or RECQL4 (1:400) overnight at 4°C. Subsequently, slides were serially washed and incubated with biotinylated secondary antibody for 1 hour at room temperature. Finally, slides were stained with DAB and counterstained with hematoxylin.
WRN or RECQL4 expression in TMAs was blindly evaluated by two pathologists using the immunoreactivity score (IRS), based on both the percentage of positive cells and the 
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Investigation of the RECQ family in breast cancer intensity of staining. The percentage of positive cells was graded as follows: 0 (negative), 1 (<10%), 2 (10%-50%), 3 (51%-80%), 4 (>80%). The intensity of staining was graded as follows: 0 (no color reaction), 1 (mild reaction), 2 (moderate reaction), 3 (intense reaction). IRS ranging from 0 to 12 was calculated by multiplication of the two scores. In this study, WRN or RECQL4 expression was defined as low (IRS ≤6) or high (IRS >6).
Data analysis
In this study, we entered five RecQ DNA-helicase family members (RECQL, BLM, WRN, RECQL4, and RECQL5) into the database (http://kmplot.com/analysis/index. php?P=service%20&cancer%20=%20breast) and analyzed them under different clinical parameters. We only selected the JetSet best probe set of five RecQ DNA-helicase family members to obtain Kaplan-Meier survival plots. mRNA expression of related genes above or below the median divides the cases into high and low expression, respectively. Associations between protein-expression levels of WRN or RECQL4 and clinicopathological features were analyzed using Pearson's χ 2 test. In both Kaplan-Meier Plotter and prognostic relevance of WRN and RECQL4 protein levels in breast cancer patients, survival analysis was estimated according to the Kaplan-Meier method and log-rank test. HR and 95% CI were calculated using the Cox proportionalhazard regression model. P<0.05 was considered statistically significant.
Results
Prognosis in patients with breast cancer and mRNA expression of the five RecQ DNA-helicase family members Patient-survival data and mRNA expression of the five RecQ family members in breast cancer patients were obtained from www.kmplot.com. OS, DMFS, RFS, and PPS curves were plotted. The prognostic significance of RECQL mRNA expression was evaluated from the data obtained (Affymetrix ID for RECQL: 212918_at). Increased mRNA-expression levels of RECQL were significantly associated with reduced RFS (HR 1.28, 95% CI 1.15-1.42; P<0.001; Figure 1A ), and reduced PPS (HR 1.32, 95% CI 1.03-1.68; P=0.027; Figure 1B ). However, mRNA-expression levels of RECQL were not significantly correlated with OS (HR 1.04, 95% CI 0.84-1.28; P=0.74) or DMFS (HR 1.06, 95% CI 0.87-1.28; P=0.57; Figure 1C and D).
The prognostic significance of BLM mRNA expression was evaluated from the data obtained (Affymetrix ID for BLM: 205733_at). Increased mRNA-expression levels of BLM were significantly associated with reduced DMFS (HR 1.28, 95% CI 1.06-1.56; P=0.011; Figure 2A) Figure 2B-D) .
The prognostic significance of WRN mRNA expression was evaluated from the data obtained (Affymetrix ID for WRN: 205667_at). Increased mRNA-expression levels of WRN were associated with improved patient OS (HR 0.76, 95% CI 0.61-0.94; P=0.011; Figure 3A ) and increased RFS (HR 0.81, 95% CI 0.73-0.91; P<0.001; Figure 3B) Figure 3C and D).
The prognostic significance of RECQL4 mRNA expression was evaluated from the data obtained (Affymetrix ID for RECQL4: 213520_at). Increased mRNA-expression levels of RECQL4 were significantly associated with reduced patient OS (HR 1.74, 95% CI 1.4-2.16; P<0.001; Figure 4A ), DMFS (HR 1.53, 95% CI 1.26-1.86; P<0.001; Figure 4B ), and RFS (HR 1.65, 95% CI 1.48-1.84; P<0.001; Figure 4C ). Also, high expression of RECQL4 mRNA was modestly correlated with poor PPS (HR 1.27, 95% CI 0.99-1.62; P=0.055; Figure 4D ), but not significantly.
The prognostic significance of RECQL5 mRNA expression was evaluated from the data obtained (Affymetrix ID for RECQL5: 221686_s_at). Increased mRNA-expression levels of RECQL5 were significantly associated with increased RFS (HR 0.83, 95% CI 0.74-0.93; P<0.001; Figure 5A) Figure 6A ). However, there was no significant difference in patient OS between patients with luminal A, luminal B, and HER2-positive type breast cancer ( Figure 6B-D) .
Increased expression levels of RECQL4 mRNA were significantly associated with reduced OS in patients with intrinsic luminal A-type breast cancer (HR 2.26, 95% CI 1.56-3.27; P<0.001; Figure 7A ) and HER2-positive breast cancer (HR 2.2, 95% CI 1.12-4.31; P=0.019; Figure 7B ). However, mRNA-expression levels of RECQL4 were not significantly correlated with prognosis in patients with intrinsic luminal B or basal-like breast cancer subtypes ( Figure 7C, D) .
As shown in Figure 8A , increased expression levels of RECQL5 mRNA were significantly associated with reduced patient OS (HR 2.09, 95% CI 1.05-4.17; P=0.032) in patients with HER2-positive breast cancer. However, expression levels of RECQL5 mRNA were not significantly correlated with OS 
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Prognosis in patients with mRNA expression of the five RecQ DNAhelicase family members and patient clinicopathological characteristics
Patient clinicopathological characteristics included tumor ER status, PR status, positive lymph-node status, grade, and TP53-mutation status. Increased RECQL4 mRNA expression was significantly correlated with reduced patient OS in ER-positive breast cancer (HR 1.9, 95% CI 1.33-2.74; P<0.001), and increased WRN mRNA expression was moderately correlated with increased patient OS in ER-negative breast cancer (HR 0.64, 95% CI 0.4-1.02; P=0.056; Table 1 ).
In patients with PR-positive breast cancer, only RECQL4 mRNA expression was significantly associated with reduced patient prognosis (HR 4.87, 95% CI 1.01-23.52; P=0.029; Table 2 ). As shown in Table 3 
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Zhu et al As shown in Table 4 , there was no significant correlation between mRNA-expression levels of the five RecQ DNA helicase family members and histopathological grades of the breast cancers. Table 5 shows that high expression levels of RECQL mRNA were significantly associated with favorable prognosis in mutant-p53-type breast cancer patients (HR 0.33, 95% CI 0.13-0.82; P=0.013).
Prognosis in patients with protein expression of WRN and RECQL4
To analyze the association between mRNA expression of RecQ family members and prognosis in breast cancer patients, we used the Kaplan-Meier Plotter database and found that high mRNA-expression levels of WRN were significantly 
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Zhu et al Figure 9C ) and patients with high RECQL4 levels displayed reduced OS (P=0.003, Figure 9D ). The results suggested that at both mRNA and protein levels, high WRN expression was correlated with increased OS and high RECQL4 expression with reduced OS.
Discussion
The aims of this study were to use a Kaplan- 
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Zhu et al member has a particular biological function in breast cancer. However, the mechanisms of how each RecQ family member contributes to breast cancer remain unknown, even though each RecQ family member has been shown to have a key role in preserving genome stability by taking effects in DNA replication, recombination, DNA-damage signaling, DNArepair pathways, and telomere maintenance. 6, 22, 23 RECQL is the smallest, but most abundant member of the human RecQ helicase family, and has been shown to be widely expressed in the cell nucleus. 24, 25 RECQL has been shown to be highly expressed in solid tumors, including glioblastoma, 26 head and neck squamous-cell carcinoma, 27 ovarian cancer, 28 hepatocellular carcinoma, 29 and squamous-cell carcinoma of the tongue. 30 RECQL has also been shown to be expressed at high levels in non-small-cell lung cancer cell lines when compared with a normal bronchial epithelial cell line, and it has been proposed to have a role in lung cancer by regulating epithelial-mesenchymal transition. 31 
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Investigation of the RECQ family in breast cancer overexpressed in multiple myeloma cells when compared with normal plasma cells, and has been shown to be associated with poor prognosis. 9 It has been hypothesized that tumors may depend on RECQL to tolerate replication-induced DNA damage. Recently, Arora et al showed that high RECQL mRNA expression was correlated with improved breast cancer-specific survival (BCSS) in patients with ER-positive breast cancer. 32 However, in this present study, there was no correlation between the mRNA expression of RECQL and prognosis in ER-positive breast cancer, but increased mRNA expression of RECQL was associated with reduced RFS and PPS in all breast cancer patients and improved OS in patients with basal-like breast cancer, and mutant-p53-type breast cancer. The controversial findings could be due to different patient cohorts and limited patient populations.
BLM is focally located to promyelocytic leukemia bodies and telomeres in the cell nucleus. 33, 34 The expression of BLM varies in the cell cycle, and is increased in the S and G 2 
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Zhu et al phases. 35 BLM is a critical helicase for DNA metabolism, replication, and repair. 6 Mutation of BLM is associated with Bloom's syndrome, which is a rare and autosomal-recessive hereditary clinical disease that is characterized by proportional dwarfism, and which can be associated with the early development of several types of cancer. 36 BLM is overexpressed in some tumor cells, and abnormalities in BLM are associated with genome instability, which has been shown in recent studies to lead to tumorigenesis. [11] [12] [13] Recently, Qian et al showed that BLM was overexpressed in prostate 
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Investigation of the RECQ family in breast cancer cancer cells and tissue compared with benign prostatic hyperplasia cells and nonprostate cancer tissue. 37 In 2015, Arora et al showed that in breast cancer, overexpression of BLM mRNA was significantly correlated with increased histopathological grade, larger tumors, ER-negative tumors, PR-negative tumors, and triple-negative tumor phenotypes, and associated with reduced BCSS. 38 BLM has a role in DNA replication and cell proliferation, 39 which may be a reason for the presence of high BLM mRNA in invasive breast cancer. The results of this present study showed that high mRNA expression of BLM was correlated with reduced DMFS, although no significant associations were found between the mRNA expression of BLM and tumor grade, ER-negative, PR-negative, or triple-negative breast cancer status. These discrepant results might be due to different methods in determining cutoffs. Second, the number of patients in our study was relatively small.
WRN is located primarily in the nucleolus in normal cells, but after DNA damage it rapidly relocates to other nuclear regions. [40] [41] [42] [43] The gene responsible for Werner's syndrome was recognized by positional cloning, 44 and in addition to having 3′→5′ helicase activity, the WRN protein also has 3′→5′ exonuclease activity, unlike other RecQ DNA helicases. 6 Loss of function of WRN can result in the clinical condition of Werner's syndrome, which is characterized by an increased incidence of tumors, including follicular thyroid carcinoma, malignant melanoma, and soft-tissue sarcoma. [45] [46] [47] The WRN gene plays an important role in DNA repair, replication, recombination, and maintenance of nuclear telomeres, which means that reduced expression of WRN results in genomic instability. [48] [49] [50] Malignant tumor cells might be able to increase WRN expression to protect the stability of their genome, as increased protein expression of WRN has been demonstrated in some cancer cell lines and knockdown of WRN to induce cell death. 51 However, there have been few studies on the role of WRN in breast cancer. In this present study, the findings showed that high levels of WRN mRNA expression were significantly associated with increased patient OS and RFS and modestly associated with increased OS in ER-negative breast cancer patients. At the protein level, we observed high WRN levels in 44.1% of breast cancers, and similarly high WRN expression was correlated with increased OS. Research on WRN has primarily focused on in vitro study, and future clinical studies are needed to validate our findings.
RECQL4 is distributed in the nucleus and cytoplasm in different types of cells and tissue.
52 RECQL4 is sometimes located in mitochondria, where it may have a role in preserving mitochondrial DNA integrity. 53, 54 Mutations in the RECQL4 gene can lead to clinical disorders, including Rothmund-Thomson syndrome, which includes growth retardation and a predisposition to cancer, and the RAPADI-LINO syndrome.
52 RECQL4 has been reported to be highly expressed in osteosarcoma cells 55 and prostate cancer cells where tumor growth was shown to be reduced by siRNAmediated suppression of RECQL4. 56 Increased expression of RECQL4 has also been previously reported in breast cancer, 16 laryngeal cancer, 57 cervical cancer, 58 and oral cancer. 59 In a previous study, increased expression of RECQL4 mRNA (51%), RecQL4 protein (23%), and RECQL4 gene amplification (30.6%) were correlated with invasive tumor characteristics and poor survival in patients with breast cancer. 60 Fang et al reported that RECQL4 might interact with survivin to regulate the survival of breast cancer cells. 16 The findings of the present study showed that high mRNA expression of RECQL4 was significantly associated with decreased OS, DMFS, and RFS in patients with breast cancer and decreased OS in patients with luminal A-type breast cancer, HER2-positive, ER-positive, and PR-positive breast cancer. At the protein level, we observed high RECQL4 levels 
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Investigation of the RECQ family in breast cancer in 37.4% of breast cancers, and similarly high expression of RECQL4 was associated with increased OS. This current study was a retrospective study, and our results require confirmation in prospective studies with larger populations. RECQL5 maintains the stability and integrity of the genome, but there are no reported hereditary diseases associated with defects in the RECQL5 gene. However, RECQL5 genetic polymorphisms have been reported to be associated with laryngeal carcinoma, 61 osteosarcoma, 62 and breast cancer. 63 Studies have shown that expression of RECQL5 is decreased in colorectal cancer 64 and osteosarcoma. 65 In 2015, Wu et al reported that RECQL5 might have a role as a tumor suppressor in osteosarcoma and as a potential target for the treatment of osteosarcoma. 65 In 2016, Patterson et al showed that RECQL5 was highly expressed in urothelial carcinoma of the bladder compared with normal bladder tissue and that overexpression of RECQL5 could promote the proliferation of normal bladder cells. In bladder cancer, increased expression of RECQL5 was associated with poor patient prognosis.
66 RECQL5 maintains genomic stability by participating in many DNA metabolic processes including DNA repair. 67 High levels of RECQL5 may promote the survival of cancer cells under DNA damage in established tumors. In a previous study in breast cancer, high mRNA-expression levels of RECQL5 were significantly correlated with poor BCSS in a whole cohort of patients with breast cancer and particularly with an ER-positive subgroup. 17 Conversely, the findings in this present study showed that increased mRNA expression of RECQL5 was significantly associated with increased RFS, especially in lymph-node-negative patients, but with reduced OS in patients with HER2-positive breast cancer. The different findings between these two studies might be due to diverse patient populations, different follow-up times, and varied methods of data analysis.
Breast cancer is known to be a heterogeneous and complicated disease with many prognostic factors, and several potential prognostic clinicopathological features and molecular markers have been investigated. 68 Currently, for patients who are diagnosed with breast cancer, the most important prognostic factors are axillary-node status, tumor size, and histological tumor grade. 69 Because intrinsic breast cancer subtypes are also associated with clinical outcome, these were included in this study, as well as including the ER and PR status of the tumors. Low expression of RECQL mRNA has previously been shown to be associated with poor BCSS in patients with ER-positive breast cancer, 32 and high BLM mRNA expression was previously reported to be correlated with poor BCSS in patients with ER-positive breast cancer and improved BCSS in patients with ER-negative breast cancer, 38 while high RECQL5 mRNA expression has previously been reported to be associated with poor BCSS in patients with ER-positive breast cancer. 17 The mechanisms by which the five RecQ helicase members in human cells (RECQL, BLM, WRN, RECQL4, and RECQL5) are activated or inhibited by different hormones, genes, or environmental or epigenetic factors in breast cancer remain to be further investigated.
Conclusion
The findings of this study showed that mRNA-expression levels of the five RecQ DNA helicase family members -RECQL, BLM, WRN, RECQL4, and RECQL5 -were significantly correlated with prognosis in breast cancer patients. These preliminary findings require further study to determine whether diagnostic, prognostic, or therapeutic biomarker targets might be developed for clinical application in breast cancer.
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